NCT05783557尚未招募3 期
A Randomized, Double-blind, Active-compared Phase Ш Clinical Trial to Evaluate Clevidipine Butyrate Injectable Emulsion in the Treatment of Hypertensive Emergency and Sub-emergency
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 入组人数
- 398
- 主要终点
- Proportion of patients whose SBP fell within the target range (SBP decreased by ≥15% and ≤25% from baseline) within 30 minutes of administration
研究概览
简要总结
A randomized, double-blind, active-compared phase Ш clinical trial to evaluate clevidipine butyrate injectable emulsion in the treatment of Hypertensive Emergency and Sub-emergency.
详细描述
This is a multicenter, randomized, double-blind, active-compared Phase III clinical study to evaluate the efficacy and safety of clevidipine butyrate injectable emulsion in the treatment of Hypertensive Emergency and Sub-emergency. The Cleviprex® will be chosen as the positive controlled medicine with the same usage of the test drug.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥18 years-old and ≤75 years-old, regardless of gender;
- •Patients with hypertensive emergency and sub-emergency requiring a rapid intravenous blood-pressure control: patients with SBP > 180 mmHg and/or DBP > 120 mmHg (requiring twice consecutive blood pressure measurements, 10 to 15 min apart), with or without target organ damage;
- •A potentially fertile patient is willing and required to use reliable contraceptive methods throughout the study period and for at least 3 months after initiation of test drug to avoid pregnancy in the female patient or in the male patient's partner;
- •Able to understand informed consent, participate in the experiment voluntarily and sign informed consent.
排除标准
- •Antihypertensive drugs have been used within 2 hours before the administration of test drugs;
- •Patients with life-threatening clinical manifestations, such as malignant arrhythmias, respiratory failure, and severe disturbance of consciousness;
- •Patients with confirmed or suspected severe aortic stenosis or aortic dissection at screening time;
- •Patients with obstructive hypertrophic cardiomyopathy and systolic heart failure at screening time;
- •Patients with acute coronary syndrome at screening or myocardial infarction within 1 month before screening;
- •Patients with acute stroke within 1 month before screening;
- •Patients with clear history of secondary hypertension;
- •Patients with lipid metabolism defects;
- •Patients with a known history of liver failure or cirrhosis;
- •Patients with chronic kidney disease (CKD) stage 5, requiring long-term regular dialysis treatment;
- •Patients who are allergic to the test drug or its ingredients, or who are intolerant to calcium channel blockers, or who are allergic to soy, soy products, eggs and egg products;
- •Patients with mental illness, mental disorder and other disorders who cannot communicate properly;
- •A history of drug abuse, drug use, or alcohol dependence;
- •Female patients who are pregnant or lactating;
- •Patients who have participated in other interventional clinical trials within 3 months prior to screening;
- •Patients who are judged by the investigators to be ineligible for this study for other factors, such as patients who could not receive intravenous infusion.
研究组 & 干预措施
Experimental Group
Experimental
Experimental Group
干预措施: Clevidipine Butyrate Injectable Emulsion (Drug)
Active-compared Group
Active Comparator
Active-compared Group
干预措施: Cleviprex® (Drug)
结局指标
主要结局
Proportion of patients whose SBP fell within the target range (SBP decreased by ≥15% and ≤25% from baseline) within 30 minutes of administration
时间窗: 30 minutes
Proportion of patients whose SBP fell within the target range (SBP decreased by ≥15% and ≤25% from baseline) within 30 minutes of administration
次要结局
- AUC above the upper limit of the target range and below the lower limit of the target range within 1 hour of administration(1 hour)
- Change of heart rate from baseline within 30 min of administration(30 minutes)
- The time for the first SBP fell within the target range (SBP decreased by ≥15% and ≤25% from baseline) within 30minutes min of within 30 minutes of administration(30 minutes)
- Proportion of patients successfully converted to oral antihypertensive therapy within 6 hours of discontinuation(6 hours)
- Total dosage of clevidipine butyrate injectable emulsion(Throughout the study period, within 72 hours)
- Incidence of adverse events (AEs)(Throughout the study period, within 72 hours)
研究者
相似试验
已完成
2 期
Safety and Efficacy of Bictegravir + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive AdultsHIV-1 InfectionNCT02397694Gilead Sciences98
Unknown
3 期
Clinical Study of Clevidipine Butyrate Injection in the Treatment of Hypertensive Emergency and Sub-emergencyHypertensive EmergencyNCT05044364Shenzhen People's Hospital10
已完成
3 期
Efficacy and Safety of Tx360® Transnasal Sphenopalatine Ganglion Block in the Treatment of Chronic MigraineHeadache, MigraineNCT03337620Tian Medical Inc.174
已完成
2 期
A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD)Multiple SclerosisNCT00436826EMD Serono Research & Development Institute, Inc.172
Unknown
2 期
Efficacy and Safety of Cladribine in Combination With CAG in Newly Diagnosed Unfit Patients With AMLElderly PatientsNewly DiagnosedAcute Myeloid LeukemiaNCT04254640Sun Yat-sen University34